Switch theme
Sign up to access all valuation multiples
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
1971
3.0K+
LTM Revenue $1.4B
LTM EBITDA $419M
$4.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Haemonetics has a last 12-month revenue (LTM) of $1.4B and a last 12-month EBITDA of $419M.
In the most recent fiscal year, Haemonetics achieved revenue of $1.4B and an EBITDA of $337M.
Haemonetics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Haemonetics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| Gross Profit | $771M | XXX | $749M | XXX | XXX | XXX |
| Gross Margin | 57% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $419M | XXX | $337M | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 25% | XXX | XXX | XXX |
| EBIT | $329M | XXX | $201M | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 15% | XXX | XXX | XXX |
| Net Profit | $232M | XXX | $168M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $918M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Haemonetics's stock price is $68.
Haemonetics has current market cap of $3.3B, and EV of $4.2B.
See Haemonetics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.2B | $3.3B | XXX | XXX | XXX | XXX | $4.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Haemonetics has market cap of $3.3B and EV of $4.2B.
Haemonetics's trades at 3.1x EV/Revenue multiple, and 13.1x EV/EBITDA.
Equity research analysts estimate Haemonetics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Haemonetics has a P/E ratio of 14.0x.
See valuation multiples for Haemonetics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.3B | XXX | $3.3B | XXX | XXX | XXX |
| EV (current) | $4.2B | XXX | $4.2B | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | 9.9x | XXX | 13.1x | XXX | XXX | XXX |
| EV/EBIT | 12.7x | XXX | 21.5x | XXX | XXX | XXX |
| EV/Gross Profit | 5.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 14.0x | XXX | 21.0x | XXX | XXX | XXX |
| EV/FCF | 26.6x | XXX | 30.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHaemonetics's last 12 month revenue growth is -2%
Haemonetics's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Haemonetics's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Haemonetics's rule of X is 25% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Haemonetics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 20% | XXX | XXX | XXX |
| Rule of 40 | 21% | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 25% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Haemonetics acquired XXX companies to date.
Last acquisition by Haemonetics was XXXXXXXX, XXXXX XXXXX XXXXXX . Haemonetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Haemonetics founded? | Haemonetics was founded in 1971. |
| Where is Haemonetics headquartered? | Haemonetics is headquartered in United States of America. |
| How many employees does Haemonetics have? | As of today, Haemonetics has 3.0K+ employees. |
| Who is the CEO of Haemonetics? | Haemonetics's CEO is Mr. Christopher A. Simon. |
| Is Haemonetics publicy listed? | Yes, Haemonetics is a public company listed on NYS. |
| What is the stock symbol of Haemonetics? | Haemonetics trades under HAE ticker. |
| When did Haemonetics go public? | Haemonetics went public in 1991. |
| Who are competitors of Haemonetics? | Similar companies to Haemonetics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Haemonetics? | Haemonetics's current market cap is $3.3B |
| What is the current revenue of Haemonetics? | Haemonetics's last 12 months revenue is $1.4B. |
| What is the current revenue growth of Haemonetics? | Haemonetics revenue growth (NTM/LTM) is -2%. |
| What is the current EV/Revenue multiple of Haemonetics? | Current revenue multiple of Haemonetics is 3.1x. |
| Is Haemonetics profitable? | Yes, Haemonetics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Haemonetics? | Haemonetics's last 12 months EBITDA is $419M. |
| What is Haemonetics's EBITDA margin? | Haemonetics's last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of Haemonetics? | Current EBITDA multiple of Haemonetics is 9.9x. |
| What is the current FCF of Haemonetics? | Haemonetics's last 12 months FCF is $157M. |
| What is Haemonetics's FCF margin? | Haemonetics's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Haemonetics? | Current FCF multiple of Haemonetics is 26.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
